Martin Edelman will investigate whether cancer associated macrophage-like cells can determine whether small or indeterminate lung nodules are cancerous or benign.
The financing will go toward further development of Klaris' phenotypic single-cell technology that can rapidly identify pathogens and determine their response to antibiotics.
Amid reporting a loss of about $2.0 million for the quarter, Celcuity also said that it had completed the development of its second test, for breast cancer, based on the CELx platform.
The firm's CEO said that by the end of the year, Celcuity will complete development of new cell-signaling function tests for breast and two other cancer types.
The cancer diagnostics company went public today on the Nasdaq with an initial public offering of 2.4 million shares, priced at $9.50 per share.
The cell-based cancer diagnostics firm said in an SEC filing that it plans to offer 2 million shares of its common stock at between $8 and $10 per share.
Its technology called CELx uses a patient's tumor cells to identify abnormal cellular activity driving their cancer and the most appropriate therapy.
Astrego Diagnostics has been founded to commercialize the technology for the rapid detection of bacterial antibiotic resistance in UTIs.
The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.
Notable is adopting Labcyte's Echo acoustic liquid handling platform to screen cancer patients' tumor cells for response to individual and combination therapies.